Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy

Current Cancer Drug Targets

Volumn 4, Issue 7, 2004, Pages 555-567

  Yoshiji, Hitoshi ^a   Kuriyama, Shigeki ^b   Noguchi, Ryuichi ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

ACE inhibitor; Angiogenesis; Angiotensin II; Cancer; Renin angiotensin system; VEGF

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; CAPTOPRIL; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE A; GELATINASE B; INTERFERON; LISINOPRIL; PENICILLAMINE; PERINDOPRIL; RAMIPRIL; RETINOID; TEMOCAPRIL; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; CANCER; CANCER INHIBITION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; PEPTIDYL-DIPEPTIDASE A;

EID: 8844248644     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332790     Document Type: Review

References (140)

1. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
2. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653-660.
3. Ferrara, N.; Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 1999, 5, 1359-1364.
4. Kerbel, R. S. Tumor angiogenesis: past, present and the near nature. Carcinogenesis 2000, 21, 505-515.
5. Kerbel, R. S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol. 2001, 19, 45S-51S.
6. Saaristo, A.; Karpanen, T.; Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19, 6122-6129.
7. Boehm, T.; Folkman, J.; Browder, T.; O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390, 404-407.
8. Kerbel, R. S. A cancer therapy resistant to resistance. Nature 1997, 390, 335-336.
9. Deplanque, G.; Harris, A. L. Anti-angiogenic agents: clinical trial design and therapies in development. Eur. J. Cancer 2000, 36, 1713-1724.
10. Korn, E. L.; Arbuck, S. G..; Pluda, J.; Simon, M. R.; Kaplan R. S.; Christian, M. C. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 2001, 19, 265-272.
11. Rosen. L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000, 5, 20-27.
12. Keshet, E.; Ben-Sasson, S. A. Anticancer drug targets: approaching angiogenesis. J. Clin. Invest. 1999, 104, 1497-1501.
13. Yoshiji, H.; Kuriyama, S.; Fukui, H. Perindopril: possible use in cancer therapy. Anticancer Drugs 2002, 13, 221-228.
14. Yoshiji, H.; Kuriyama, S.; Fukui, H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002, 23, 348-356.
15. Harris, S. R.; Thorgeirsson, U. P. Tumor angiogenesis: biology and therapeutic prospects. In Vivo 1998, 12, 563-570.
16. Fox, S. B.; Gatter, K. C.; Harris, A. L. Tumour angiogenesis. J. Pathol. 1996, 179, 232-237.
17. Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
18. Shibuya, M. Structure and function of VEGF/VEGF-receptor System involved in angiogenesis. Cell Struct. Funct. 2001, 26, 25-35.
19. Bruns, C. J.; Liu, W.; Davis, D. W.; Shaheen, R. M.; McConkey, D. J.; Wilson, M. R.; Bucana, C. D.; Hicklin; D. J.; Ellis L. M. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000, 89, 488-499.
20. Befeler, A. S.; Di Bisceglie, A. M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122, 1609-1619.
21. Schafer, D. F.; Sorrell, M. F. Hepatocellular carcinoma. Lancet 1999, 353, 1253-1257.
22. Chow, N. H.; Hsu, P. I.; Lin, X. Z.; Yang, H. B.; Chan, S. H.; Cheng, K. S.; Huang, S. M.; Su, I. J. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum. Pathol. 1997, 28, 698-703.
23. Mise, M.; Arii, S.; Higashituji, H.; Furutani, M.; Niwano, M.; Harada, T.; Ishigami, S.; Toda, Y.; Nakayama, H.; Fukumoto, M.; Fujita, J.; Imamura, M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23, 455-464.
24. Miura, H.; Miyazaki, T.; Kuroda, M.; Oka, T.; Machinami, R.; Kodama, T.; Shibuya, M.; Makuuchi, M.; Yazaki, Y.; Ohnishi, S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 1997, 27, 854-861.
25. Suzuki, K.; Hayashi, N.; Miyamoto, Y.; Yamamoto, M.; Ohkawa, K.; Ito, Y.; Sasaki, Y.; Yamaguchi, Y.; Nakase, H.; Noda, K.; Enomoto, N.; Arai, K.; Yamada, Y.; Yoshihara, H.; Tujimura, T.; Kawano, K.; Yoshikawa, K.; Kamada. T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996, 56, 3004-3009.
26. Yamaguchi, R.; Yano, H.; Nakashima, Y.; Ogasawara, S.; Higaki, K.; Akiba, J.; Hicklin, D. J.; Kojiro, M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol. Rep. 2000, 7, 725-729.
27. Yamaguchi, R.; Yano, H.; Iemura, A.; Ogasawara, S.; Haramaki, M.; Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28, 68-77.
28. Gossen, M.; Bujard, H. Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc. Natl. Acad. Sci. USA 1992, 89, 5547-5551.
29. Paulus, W.; Baur, I.; Boyce, F. M.; Breakefield, X. O.; Reeves, S. A. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virol. 1996, 70, 62-67.
30. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Yamazaki, M.; Kikukawa, M.; Tsujinoue, H.; Nakatani, T.; Fukui, H. Vascular endothelial growth factor tightly regulates In vivo development of murine hepatocellular carcinoma cells. Hepatology 1998, 28, 1489-1496.
31. Ferrara, N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol. 2000, 11, 617-624.
32. Karkkainen, M. J.; Petrova, T. V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19, 5598-605.
33. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, 242-248.
34. Fong, H.; Rossant, J.; Gertsenstein, M.; Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376, 66-70.
35. Millauer, B.; Longhi, M. P.; Plate, K. H.; Shawver, L. K.; Risau, W.; Ullrich, A.; Strawn, L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 1996, 56, 1615-1620.
36. Skobe, M.; Rockwell, P.; Goldstein, N.; Vosseler, S.; Fusenig, N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 1997, 3, 1222-1227.
37. Yoshiji, H.; Kuriyama, S.; Hicklin, D. J.; Huber, J.; Yoshii, J.; Miyamoto, Y.; Kawata, M.; Ikenaka, Y.; Nakatani, T.; Tsujinoue, H.; Fukui, H. KDR/Flk-1 is a major regulator of vascular endothelial growth factor- induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 1999, 30, 1179-1186.
38. Shibuya, M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J. Biochem. Cell Biol. 2001, 33, 409-420.
39. Hiratsuka, S.; Minowa, O.; Kuno, J.; Noda, T.; Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 1998, 95, 9349-9354.
40. Hiratsuka, S.; Maru, Y.; Okada, A.; Seiki, M.; Noda, T.; Shibuya, M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001, 61, 1207-1213.
41. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J. M.; Senior, R. M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2, 289-300.
42. Luttun, A.; Tjwa, M.; Moons, L.; Wu, Y.; Angelillo-Scherrer, A.; Liao, F.; Nagy, J. A.; Hooper, A.; Priller, J.; De Klerck, B.; Compernolle, V.; Daci, E.; Bohlen, P.; Dewerchin, M.; Herbert, J. M.; Fava, R.; Matthys, P.; Carmeliet, G.; Collen, D.; Dvorak, H. F.; Hicklin, D. J.; Carmeliet, P. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 2002, 8, 831-840.
43. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Masaki, T.; Fukui, H. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J. Hepatol. 2004, 41, 97-103.
44. Xia, P.; Aiello, L. P.; Ishii, H.; Jiang, Z. Y.; Park, D. J.; Robinson, G. S.; Takagi, H.; Newsome, W. P.; Jirousek, M. R.; King, G. L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 1996, 98, 2018-2026.
45. Ishii, H.; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S. E.; Kern, T. S.; Ballas, L. M.; Heath, W. F.; Stramm, L. E.; Feener, E. P.; King, G. L.; Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272, 728-731.
46. Takahashi, T.; Shibuya, M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997, 14, 2079-2089.
47. Takahashi, T.; Ueno, H.; Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK- MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999, 18, 2221-2230.
48. Yoshiji, H.; Kuriyama, S.; Ways, D. K.; Yoshii, J.; Miyamoto, Y.; Kawata, M.; Ikenaka, Y.; Tsujinoue, H.; Nakatani, T.; Shibuya, M.; Fukui, H. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 1999, 59, 4413-4418.
49. Kanno, S.; Oda, N.; Abe, M.; Terai, Y.; Ito, M.; Shitara, K.; Tabayashi, K.; Shibuya, M.; Sato, Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000, 19, 2138-2146.
50. Luo, J. C.; Toyoda, M.; Shibuya, M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998, 58, 2594-2600.
51. Mesiano, S.; Ferrara, N.; Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 1998, 153, 1249-1256.
52. Nagy, J. A.; Masse, E. M.; Herzberg, K. T.; Meyers, M. S.; Yeo, K. T.; Yeo, T. K.; Sioussat, T. M.; Dvorak, H. F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 1995, 55, 360-368.
53. Luo, J. C.; Yamaguchi, S.; Shinkai, A., Shitara, K.; Shibuya, M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998, 58, 2652-2660.
54. Yoshiji, H.; Kuriyama, S.; Hicklin, D. J.; Huber, J.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001, 33, 841-847.
55. Li, C. Y.; Shan, S.; Huang, Q.; Braun, R. D.; Lanzen, J.; Hu, K.; Lin, P.; Dewhirst, M. W. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J. Natl. Cancer Inst. 2000, 92, 143-147.
56. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410.
57. Bergers, G.; Javaherian, K.; Lo, K. M.; Folkman, J.; Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284, 808-812.
58. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
59. Park, Y. N.; Kim, Y. B.; Yang, K. M.; Park, C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 2000, 124, 1061-1065.
60. Frachon, S.; Gouysse, G.; Dumorti, J.; Couvelard, A.; Nejjari, M.; Mion, F.; Berger, F.; Paliard, P.; Boillot, O.; Scoazec, J. Y. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J. Hepatol. 2001, 34, 850-857.
61. Kin, M.; Torimura, T.; Ueno, T.; Nakamura, T.; Ogata, R.; Sakamoto, M.; Tamaki, S.; Sata, M. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int. J. Oncol. 2000, 16, 375-382.
62. Yoshiji, H.; Kuriyama S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Masaki, T.; Fukui, H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39, 1517-1524.
63. Gospodarowicz, D. Fibroblast growth factor. Chemical structure and biologic function. Clin. Orthop. 1990, 231-248.
64. Nugent, M. A.; Iozzo, R. V. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32, 115-120.
65. Kandel, J.; Bossy-Wetzel, E.; Radvanyi, F.; Klagsbrun, M.; Folkman, J.; Hanahan, D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66, 1095-1104.
66. Hata, Y.; Rook, S. L.; Aiello, L. P. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 1999, 48, 1145-1155.
67. Seghezzi, G.; Patel, S.; Ren, C. J.; Gualandris, A.; Pintucci, G.; Robbins, E. S.; Shapiro, R. L.; Galloway, A. C.; Rifkin, D. B.; Mignatti, P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 1998, 141, 1659-1673.
68. Majima, M.; Hayashi, I.; Muramatsu, M.; Katada, J.; Yamashina, S.; Katori, M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br. J. Pharmacol. 2000, 130, 641-649.
69. Asahara, T.; Bauters, C.; Zheng, L. P.; Takeshita, S.; Bunting, S.; Ferrara, N. J. Symes, F.; Isner, J. M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92, 11365-11371.
70. Coltrini, D.; Gualandris, A.; Nelli, E. E.; Parolini, S.; Molinari-Tosatti, M. P.; Quarto, N.; Ziche, M.; Giavazzi, R.; Presta, M. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res. 1995, 55, 4729-4738.
71. Compagni, A.; Wilgenbus, P.; Impagnatiello, M. A.; Cotton, M.; Christofori, G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60, 7163-7169.
72. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 1999, 237, 1-30.
73. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Huber, J.; Nakatani, T.; Tsujinoue, H.; Yanase, K.; Imazu, H.; Fukui, H. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002, 35, 834-842.
74. Matsusaka, T.; Ichikawa, I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 1997, 59, 395-412.
75. Piepho, R. W. Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health Syst. Pharm. 2000, 57 Suppl. 1, S3-S7.
76. Stoll, M.; Unger, T. Angiotensin and its AT2 receptor: new insights into an old system. Regul. Pept. 2001, 99, 175-182.
77. Zhang, X.; Lassila, M.; Cooper, M. E.; Cao, Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004, 43, 276-281.
78. Lever, A. F.; Hole, D. J.; Gillis, C. R.; McCallum, I. R.; McInnes, G. T.; MacKinnon, P. L.; Meredith, P. A.; Murray, L. S.; Reid, J. L.; Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352, 179-184.
79. Hii, S. I.; Nicol, D. L.; Gotley, D. C.; Thompson, L. C.; Green, M. K.; Jonsson, J. R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 1998, 77, 880-883.
80. Volpert, O. V.; Ward, W. F.; Lingen, M. W.; Chester, L.; Solt, D. B.; Johnson, M. D.; Molteni, A.; Polverini, P. J.; Bouck, N. P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996, 98, 671-679.
81. Yoshiji, H.; Kuriyama, S.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. The angiotensin-i-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001, 7, 1073-1078.
82. Chen, L.; Re, R. N.; Prakash, O.; Mondal, D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc. Soc. Exp. Biol. Med. 1991, 196, 280-283.
83. Lindberg, H.; Nielsen, D.; Jensen, B. V.; Eriksen, J.; Skovsgaard, T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol. 2004, 43, 142-152.
84. Chaturvedi, N.; Sjolie, A. K.; Stephenson, J. M.; Abrahamian, H.; Keipes, M.; Castellarin, A.; Rogulja-Pepeonik, Z.; Fuller, J. H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351, 28-31.
85. Gilbert, R. E.; Kelly, D. J.; Cox, A. J.; Wilkinson-Berka, J. L.; Rumble, J. R.; Osicka, T.; Panagiotopoulos, S.; Lee, V.; Hendrich, E. C.; Jerums, G.; Cooper, M. E. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000, 43, 1360-1367.
86. Otani, A.; Takagi, H.; Suzuma, K.; Honda, Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 1998, 82, 619-628.
87. Kardum, D.; Huskic, J.; Fabijanic, D.; Banic, M.; Buljevac, M.; Kujundzic, M.; Loncar, B. Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma. Eur. J. Gastroenterol Hepatol. 1999, 11, 1209-1213.
88. Medeiros, R.; Vasconcelos, A.; Costa, S.; Pinto, D.; Lobo, F.; Morais, A.; Oliveira, J.; Lopes, C. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J. Pathol. 2004, 202, 330-335.
89. Monton, M.; Castilla, M. A.; Alvarez Arroyo, M. V.; Tan, D.; Gonzalez-Pacheco, F. R.; Lopez Farre, A.; Casado, S.; Caramelo, C. Effects of angiotensin II on endothelial cell growth: role of AT-1 and AT-2 receptors. J. Am. Soc. Nephrol. 1998, 9, 969-974.
90. Yoshiji, H.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Tsujinoue, H.; Imazu, H.; Fukui, H. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 2002, 20, 1227-1231.
91. Ardaillou, R. Angiotensin II receptors. J. Am. Soc. Nephrol. 1999, 10 Suppl. 11, S30-S39.
92. Kerins, D. M.; Hao, Q.; Vaughan, D. E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J. Clin. Invest. 1995, 96, 2515-2520.
93. Fukumura, D.; Xavier, R.; Sugiura, T.; Chen, Y.; Park, E. C.; Lu, N.; Selig, M.; Nielsen, G.; Taksir, T.; Jain, R. K.; Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94, 715-725.
94. Cooper, M. E.; Cao, Z.; Rumble, J. R.; Jandeleit, K.; Allen, T. J.; Gilbert, R. E. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism 1998, 47, 24-27.
95. Dixon, I. M.; Ju, H.; Jassal, D. S.; Peterson, D. J. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol. Cell Biochem. 1996, 165, 31-45.
96. Fujita, M.; Hayashi, I.; Yamashina, S.; Itoman, M.; Majima, M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem. Biophys. Res. Commun. 2002, 294, 441-447.
97. Nakagawa, T.; Kubota, T.; Kabuto, M.; Kodera, T. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res. 1995, 15, 1985-1989.
98. Sorbi, D.; Fadly, M.; Hicks, R.; Alexander S.; Arbeit, L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 1993, 44, 1266-1272.
99. Gately, S.; Twardowski, P.; Stack, M. S.; Cundiff, D. L.; Grella, D.; Castellino, F. J.; Enghild, J.; Kwaan, H. C.; Lee, F.; Kramer, R. A.; Volpert, O.; Bouck, N.; Soff, G. A. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 1997, 94, 10868-10872.
100. McMurray, J.; Chopra, M. Influence of ACE inhibitors on free radicals and reperfusion injury: pharmacological curiosity or therapeutic hope? Br. J. Clin. Pharmacol. 1991, 31, 373-379.
101. Wartenberg, M.; Budde, P.; De Marees, M.; Grunheck, F.; Tsang, S. Y.; Huang, Y.; Chen, Z. Y.; Hescheler, J.; Sauer, H. Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional Chinese medicine. Lab. Invest. 2003, 83, 87-98.
102. O'Reilly, M. S.; Holmgren, L.; Chen, C.; Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 1996, 2, 689-692.
103. Scappaticci, F. A.; Smith, R.; Pathak, A.; Sehloss, D.; Lum, B.; Cao, Y.; Johnson, F.; Engleman, E. G.; Nolan, G. P. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 2001, 3, 186-196.
104. Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002, 20, 3906-3927.
105. Minischetti, M.; Vacca, A.; Ribatti, D.; Iurlaro, M.; Ria, R.; Pellegrino, A.; Gasparini, G.; Dammacco, A. F. TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br. J. Haematol. 2000, 109, 829-837.
106. Noguchi, R.; Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Mitoro, A.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 2003, 9, 6038-6045.
107. Bolontrade, M. F.; Stern, M. C.; Binder, R. L.; Zenklusen, J. C.; Gimenez-Conti, I. B.; Conti, C. J. Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 1998, 19, 2107-2113.
108. Yoshiji, H.; Nakae, D.; Kinugasa, T.; Matsuzaki, M.; Denda, A.; Tsujii, T.; Konishi, Y. Inhibitory effect of dietary iron deficiency on the induction of putative preneoplastic foci in rat liver initiated with diethylnitrosamine and promoted by phenobarbital. Br. J. Cancer 1991, 64, 839-842.
109. Yoshiji, H.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Tsujinoue, H.; Nakatani, T.; Imazu, H.; Yanase, K.; Kuriyama, S.; Fukui, H. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. 2002, 37, 22-30.
110. Ikeda, K.; Arase, Y.; Saitoh, S.; Kobayashi, M.; Suzuki, Y.; Suzuki, F.; Tsubota, A.; Chayama, K.; Murashima, N.; Kumada, H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32, 228-232.
111. Muto, Y.; Moriwaki, H.; Ninomiya, M.; Adachi, S.; Saito, A.; Takasaki, K. T.; Tanaka, T.; Tsurumi, K.; Okuno, M.; Tomita, E.; Nakamura, T.; Kojima, T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 1996, 334, 1561-1567.
112. Boudreau, N.; Bissell, M. J. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 1998, 10, 640-646.
113. Theret, N.; Musso, O.; Turlin, B.; Lotrian, D.; Bioulac-Sage, P.; Campion, J. P.; Boudjema, K.; Clement, B. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001, 34, 82-88.
114. Sakaida, I.; Hironaka, K.; Uchida, K.; Suzuki, C.; Kayano, K.; Okita, K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 1998, 28, 1247-1252.
115. Tharaux, P. L.; Chatziantoniou, C.; Fakhouri, F.; Dussaule, J. C. Angiotensin II activates collagen 1 gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000, 36, 330-336.
116. Arthur, M. J. Degradation of matrix proteins in liver fibrosis. Pathol. Res. Pract. 1994, 190, 825-833.
117. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34, 745-750.
118. Bataller, R.; Gines, P.; Nicolas, J. M.; Gorbig, M. N.; Garcia-Ramallo, E.; Gasull, X.; Bosch, J.; Arroyo, V.; Rodes, J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118, 1149-1156.
119. Nakae, D.; Yoshiji, H.; Mizumoto, Y.; Horiguchi, K.; Shiraiwa, K.; Tamura, K.; Denda, A.; Konishi, Y. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res. 1992, 52, 5042-5045.
120. Iredale, J. P. Tissue inhibitors of metalloproteinases in liver fibrosis. Int. J. Biochem. Cell Biol. 1997, 29, 43-54.
121. Yoshiji, H.; Kuriyama, S.; Miyamoto, Y.; Thorgeirsson, U. P.; Gomez, D. E.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Tsujinoue, H.; Nakatani, T.; Thorgeirsson, S. S.; Fukui, H. Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Fibrosis Development in a Transgenic Mouse Model. Hepatology 2000, 32, 1248-1254.
122. Iredale, J. P.; Benyon, R. C.; Pickering, J.; McCullen, M.; Northrop, M.; Pawley, S.; Hovell, C.; Arthur, M. J. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 1998, 102, 538-549.
123. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Yanase, K.; Namisaki, T.; Imazu, H.; Fukui, H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002, 36, 850-860.
124. Chua, C. C.; Hamdy, R. C.; Chua, B. H. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochi. Biophy. Acta 1996, 1311, 175-180.
125. Kalluri, R.; Sukhatme, V. P. Fibrosis and angiogenesis. Curr. Opin. Nephrol. Hypertens. 2000, 9, 413-418.
126. Ohmori, S.; Shiraki, K.; Sugimoto, K.; Sakai, T.; Fujikawa, K.; Wagayama, H.; Takase, K.; Nakano, T. High expression of CD34-positive sinusoidal endothelial cells is a risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases. Hum. Pathol. 2001, 32, 1363-1370.
127. Corpechot, C.; Barbu, V.; Wendum, D.; Kinnman, N.; Rey, C.; Poupon, R.; Housset, C.; Rosmorduc, O. Hypoxia-induced VEGF and collagen 1 expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35, 1010-1021.
128. Rosmorduc, O.; Wendum, D.; Corpechot, C.; Galy, B.; Sebbagh, N.; Raleigh, J.; Housset, C.; Poupon, R. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am. J. Pathol. 1999, 155, 1065-1073.
129. Wang, Y. Q.; Ikeda, K.; Ikebe, T.; Hirakawa, K.; Sowa, M.; Nakatani, K.; Kawada, N.; Kaneda, K. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 2000, 32, 980-989.
130. Friedman, S. L. Cytokines and fibrogenesis. Semin. Liver Dis. 1999, 19, 129-140.
131. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52, 1347-1354.
132. Yoshiji, H.; Harris, S. R.; Raso, E.; Gomez, D. E.; Lindsay, C. K.; Shibuya, M.; Sinha C. C.; Thorgeirsson, U. P. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int. J. Cancer 1998, 75, 81-87.
133. Fabre, J. E.; Rivard, A.; Magner, M.; Silver, M.; Isner, J. M. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999, 99, 3043-3049.
134. Silvestre, J. S.; Bergaya, S.; Tamarat, R.; Duriez, M.; Boulanger, C. M.; Levy, B. I. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ. Res. 2001, 89, 678-683.
135. Xin, X.; Yang, S.; Ingle, G.; Zlot, C.; Rangell, L.; Kowalski, J.; Schwall, R.; Ferrara, N.; Gerritsen, M. E. Hepatocyte growth factor enhances vascular endothelial growth factor- induced angiogenesis in vitro and in vivo. Am. J. Pathol. 2001, 158, 1111-1120.
136. Yasuda, S.; Goto, Y.; Sumida, H.; Noguchi, T.; Baba, T.; Miyazaki, S.; Nonogi, H. Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Hypertension 1999, 33, 1374-1378.
137. St Croix, B.; Rago, C.; Velculescu, V.; Traverso, G.; Romans, K. E.; Montgomery, E.; Lal, A.; Riggins, G. J.; Lengauer, C.; Vogelstein B.; Kinzler, K. W. Genes expressed in human tumor endothelium. Science 2000, 289, 1197-1202.
138. Powell, E. E.; Edwards-Smith, C. J.; Hay, J. L.; Clouston, A. D.; Crawford, D. H.; Shorthouse, C.; Purdie, D. M.; Jonsson, J. R. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31, 828-833.
139. Friis, S.; Sorensen, H. T.; Mellemkjaer, L.; McLaughlin, J. K.; Nielsen, G. L.; Blot, W. J.; Olsen, J. H. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001, 92, 2462-2470.
140. Progress-Collaborative-Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358, 1033-1041.